Personalized mRNA Cancer Vaccines Enter Phase 3 Trials for Melanoma and Pancreatic Cancer

Personalized mRNA cancer vaccines have entered Phase 3 clinical trials for melanoma and pancreatic cancer as of late 2026. The vaccines work by training the immune system to recognize and attack tumor mutations specific to each patient.

Unlike traditional cancer treatments, these vaccines are custom-built for each individual. Researchers sequence the patient's tumor DNA, identify unique mutations, and design an mRNA sequence that instructs the immune system to target those specific markers.

Earlier phase trials showed significant results. In melanoma patients, the personalized vaccine combined with immunotherapy reduced the risk of recurrence or death by 44 percent compared to immunotherapy alone. Pancreatic cancer results were also encouraging, with some patients showing durable responses in a disease that typically has a poor prognosis.

The Phase 3 trials will enroll thousands of patients across multiple countries. Researchers expect results within two to three years. If successful, the vaccines could receive regulatory approval and become available to patients by the early 2030s.

Moderna and Merck are among the companies leading development of personalized mRNA cancer vaccines. The technology builds on the mRNA platform used to develop COVID-19 vaccines, which proved the approach could work at scale.

Oncologists say the personalized approach represents a shift in how cancer is treated. Rather than targeting cancer broadly, the vaccines go after the specific genetic fingerprint of each patient's tumor.

The cost of manufacturing personalized vaccines remains a challenge. Each vaccine must be produced individually, which is more expensive than mass-produced treatments. Researchers are working on ways to reduce production time and cost.